July 30, 2018 was a game-changing day for the many migraine-sufferers around Europe and the world, as a new type of medicine aimed to prevent migraines was approved by the European Commission.
The medicine is called Aimovig® or erenumab and it was approved by the European Commission for the prevention of migraine in adults experiencing four or more migraine days per month.
While erenumab was approved by the US FDA back in May 2018 and the Australian TGA on July 3rd 2018, it had yet to be approved by the EMA – until now.
What makes Aimovig® special compared to other migraine treatments?
Aimovig® is the first migraine treatment that works by blocking a specific receptor called the calcitonin gene-related peptide receptor (CGRP-R), which is thought to play a critical role in transmitting pain signals associated with migraine. As such, it is the first migraine treatment that works to prevent migraine instead of treating the symptoms when occurring.
Moreover, Aimovig® is the very first of its kind to have been studied in patients who had previously not been prone to treatment.
What did the clinical trial show?
Aimovig® was studied in an extensive clinical programme involving 2,600 patients. The study showed significant reductions in the frequency of migraines, while demonstrating a similar safety profile as placebo. Moreover, in an interim analysis of a 5-year open label extension in episodic migraine, it was demonstrated that after 15 months of injecting Aimovig® 70 mg, one in four patients was completely migraine free.
Aimovig® can be self-administered and should be injected once every four weeks.
If you have any questions regarding erenumab or any other medicine, please contact us here
Aimovig® is a registered trademark of Novartis and Amgen. Amgen has exclusive commercial rights in Japan, Novartis and Amgen co-commercialise in the US and Novartis has exclusive rights in the rest of the world.